European Society for Medical Oncology (ESMOCongress Roche Analyst Audio Webcast Monday, 22 October 2018 Welcome Daniel O’Day, CEO Roche Pharmaceuticals

First Page		Document Content
Medicine Clinical medicine Cancer Tyrosine kinase receptors Breast cancer Atezolizumab ROS1 Triple-negative breast cancer Anaplastic lymphoma kinase Trastuzumab emtansine Entrectinib Metastatic breast cancer		European Society for Medical Oncology (ESMOCongress Roche Analyst Audio Webcast Monday, 22 October 2018 Welcome Daniel O’Day, CEO Roche Pharmaceuticals Add to Reading List Source URL: www.roche.com Download Document from Source Website File Size: 2,40 MB Share Document on Facebook

	Microsoft Word - abstracts_compiled.doc DocID: 1rn3E - View Document
	Abstract ErbB2 overexpression gives rise to a highly invasive, aggressive phenotype associated with an enlarged lysosomal compartment and increased activity of the lysosomal proteases, cysteine cathepsins. We have recent DocID: 1rdcC - View Document
	CME A Look at the Near Future of Lung Cancer Treatment Dates of certification: May 31, 2016, to May 31, 2017 Medium: Print with online posttest, evaluation, and request for credit DocID: 1qVsW - View Document
	2014 Annual Report Centre for Cancer Biology DocID: 1qRyU - View Document
	Wrangling Phosphoproteomic Data to Elucidate Cancer Signaling Pathways Mark L. Grimes1*, Wan-Jui Lee2, Laurens van der Maaten2, Paul Shannon3 1 Division of Biological Sciences, University of Montana, Missoula, Montana, U DocID: 1qMPs - View Document